S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

MRKR Marker Therapeutics Inc

4.22

0.02 (0.48%)

May 03 2024 - Closed

Delayed by 15 minutes

Confidential Treatment Order (ct Order)

This regulatory filing also includes additional resources:
filename1.pdf

Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Marker Therapeutics Charts.

Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Marker Therapeutics Charts.

Marker Therapeutics, Inc. News

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
Monday 8 April 2024 (4 weeks ago) • GlobeNewswire Inc.

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Monday 25 March 2024 (1 month ago) • GlobeNewswire Inc.

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Friday 22 March 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 26 February 2024 (2 months ago) • Edgar (US Regulatory)

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
Monday 22 January 2024 (3 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 8 January 2024 (4 months ago) • Edgar (US Regulatory)

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Monday 8 January 2024 (4 months ago) • GlobeNewswire Inc.

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
Thursday 21 December 2023 (4 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 11 December 2023 (5 months ago) • Edgar (US Regulatory)

Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
Monday 11 December 2023 (5 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 20 November 2023 (5 months ago) • Edgar (US Regulatory)

More Marker Therapeutics, Inc. News Articles

Code Green Apparel (PK)

Kraig Biocraft Laborator... (QB)

Voip Pal Com (QB)

1812 Brewing (PK)

AMC Entertainment

Trump Media and Technology

Digital Brand Media and ... (PK)

Rennova Health (PK)

Anavex Life Sciences

Asia Broadband (PK)

Northwest Biotherapeutics (QB)

Impact Fusion (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions